Buyang Huanwu decoction ameliorates coronary heart disease with Qi deficiency and blood stasis syndrome by reducing CRP and CD40 in rats

被引:79
作者
Zhang, Hui [1 ]
Wang, Wei-Rong [1 ]
Lin, Rong [1 ]
Zhang, Ji-Ye [1 ]
Ji, Qiao-Li [1 ]
Lin, Qin-Qin [1 ]
Yang, Li-Na [1 ]
机构
[1] Xi An Jiao Tong Univ, Sch Med, Dept Pharmacol, Key Lab Environm & Genes Related Dis, Xian 710061, Shaanxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Buyang Huanwu decoction (BYHWD); C-reactive protein (CRP); Cluster of differentiation 40 (CD40); Endothelium-derived vasoactive factors; Coronary heart disease (CHD); C-REACTIVE PROTEIN; NITRIC-OXIDE; INFLAMMATION; RISK; STRESS; LIGAND;
D O I
10.1016/j.jep.2010.04.017
中图分类号
Q94 [植物学];
学科分类号
071001 ;
摘要
Ethnopharmacological relevance: Qi deficiency and blood stasis is traditional Chinese medicine (TCM) syndrome. It leads to many diseases including coronary heart diseases (CHD) and cerebrovascular diseases (CVD). Inflammatory biomarkers and many endothelium-derived vasoactive factors are considered to play pivotal roles in CHD. Buyang Huanwu decoction (BYHWD), a TCM formula, has been recognized as a treatment for CHD with Qi deficiency and blood stasis syndrome and CVD in clinic. The mechanisms of BYHWD effect on CHD with Qi deficiency and blood stasis syndrome are unclear. Aim of the study: The aim is to investigate whether the effects of BYHWD on CHD with Qi deficiency and blood stasis syndrome in rats are associated with the inhibition of CRP, CD40 and vascular endothelial regulators. Materials and methods: The treated groups were lavaged with 25.68, 12.84 and 6.42 g/kg BYHWD respectively once a day for 21 days. The level of C-reactive protein (CRP) in serum and the expression of cluster of differentiation 40 (CD40) in the heart and aorta of rats were detected. Moreover, the levels of thromboxaneA(2) (TXA(2)) and prostacyclin (PGI(2)) in plasma were measured and the levels of inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) in serum were detected. Results: BYHWD (25.68 g/kg) significantly decreased the level of CRP in serum and BYHWD (25.68 and 12.84 g/kg) decreased the expression of CD40 in the heart and aorta (P < 0.01). The results also revealed that BYHWD (25.68 g/kg) inhibited the levels of iNOS in serum and TXA(2) in plasma and increased the levels of eNOS in serum and PGI(2) in plasma (P < 0.01). Conclusion: The study shows that the ameliorative effects of BYHWD on CHD with Qi deficiency and blood stasis syndrome in rats are associated with the inhibition of CRP and CD40 and the regulation of endothelium-derived vasoactive factors. (C) 2010 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:98 / 102
页数:5
相关论文
共 33 条
  • [1] CD40: A new marker in coronary heart disease
    Blaton, V.
    [J]. SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2007, 67 (02) : 113 - 113
  • [2] Buyang Huanwu Decoction can improve recovery of neurological function, reduce infarction volume, stimulate neural proliferation and modulate VEGF and Flk1 expressions in transient focal cerebral ischaemic rat brains
    Cai, Guangxian
    Liu, Baiyan
    Liu, Wei
    Tan, Xianhui
    Rong, Jianhui
    Chen, Xuemei
    Tong, Li
    Shen, Jiangang
    [J]. JOURNAL OF ETHNOPHARMACOLOGY, 2007, 113 (02) : 292 - 299
  • [3] Cal D.M., 2004, MODERN MED J, V32, P25
  • [4] CHAI CZ, 2010, MICE EXPOSED CHRONIC
  • [5] Simulation of steel coil heat transfer in a high performance hydrogen furnace
    Chen, Guang
    Gu, Mingyan
    [J]. HEAT TRANSFER ENGINEERING, 2007, 28 (01) : 25 - 30
  • [6] Chinese Pharmacopoeia Commission, 2000, PHARM PEOPL REP CHIN
  • [7] C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease
    Danesh, J
    Wheeler, JG
    Hirschfield, GM
    Eda, S
    Eiriksdottir, G
    Rumley, A
    Lowe, GDO
    Pepys, MB
    Gudnason, V
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (14) : 1387 - 1397
  • [8] de Leval X, 2004, CURR MED CHEM, V11, P1243
  • [9] Diagnostic value of CRP and Lp(a) in coronary heart disease
    Erbagci, AB
    Tarakçioglu, M
    Aksoy, M
    Kocabas, R
    Nacak, M
    Aynacioglu, AS
    Sivrikoz, C
    [J]. ACTA CARDIOLOGICA, 2002, 57 (03) : 197 - 204
  • [10] MATERNAL AND FETAL ATRIAL-NATRIURETIC-PEPTIDE LEVELS, MATERNAL PLASMA-RENIN ACTIVITY, ANGIOTENSIN-II, PROSTACYCLIN AND THROMBOXANE-A2 LEVELS IN NORMAL AND PREECLAMPTIC PREGNANCIES
    FURUHASHI, N
    TSUJIEI, M
    KIMURA, H
    YAJIMA, A
    NAGAE, H
    KIMURA, C
    [J]. TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 1991, 165 (02) : 79 - 86